Key points of EULAR 2020 Reports, Which Were Based on data from National Registry of Patients with Arthritis (OREL)

Дата публикации: 6 june 2020

Below you can find the links to the key points of EULAR 2020 reports, which were based on data from  National Registry of Patients with Arthritis (OREL)», which was developed by Aston Health and is supervised by Association of Rheumatologists of Russia.

Comparable efficacy and safety of two regimens of rheumatoid arthritis treatment with tofacitinib: DATA FROM RUSSIAN NATIONAL REGISTRY

Similar efficacy of tofacitinib therapy in biologic naive and had prior biologic use history patients with rheumatoid arthritis (OREL REGISTER)

А very early (7-28 days) response on jak inhibitor tofacitinib in patients with active rheumatoid arthritis: EFFECT ON PAIN AND CENTRAL SENSITIZATION

Features of clinical manifestations in patients with active rheumatoid arthritis in the presence of signs of central sensitization

Efficacy and safety of tofacitinib monotherapy and with methotrexate combination. DATA FROM NATIONAL RHEUMATOID ARTHRITIS REGISTER

Survival of remission or low disease activity in rheumatoid arthritis patients treated with tofacitinib. RESULTS OF RUSSIAN NATIONAL REGISTER

Long-term effectiveness of tofacitinib in conventional dmards non-responders with rheumatoid arthritis: RESULTS OF RUSSIAN NATIONAL REGISTER

Comparative effectiveness of tofacitinib (TF) and adalimumab (ADA) in psoriatic arthritis (PsA) patients in real clinical practice

ASSOCIATION OF ACTIVE MRI SACROILIITIS WITH DACTYLITIS AND WORK PRODUCTIVITY IMPAIRMENT IN PSORIATIC ARTHRITIS PATIENTS. POSITIVE EFFECTS OF TOFACITINIB TREATMENT. DATA FROM CLINICAL PRACTICE

EFFECT OF TOFACITINIB TREATMENT ON ACTIVE MRI SACROILIITIS AND DISEASE ACTIVITY REDUCTION IN PSORIATIC ARTHRITIS PATIENTS. DATA FROM CLINICAL PRACTICE

Tofacitinib improves disease activity and patient-reported outcomes (PROs) in patients (pts) with active psoriatic arthritis (PsA) IN REAL CLINICAL PRACTICE